转移性前列腺癌-话题@MedSci

#转移性前列腺癌#

60篇内容 | 2304人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1395552, encodeId=1c7113955523b, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=J Clin Oncol：恩扎鲁胺治疗转移性前列腺癌时18氟化钠PET/CT和循环肿瘤细胞的时空变化, objectType=article, longId=200818, objectId=cdcb20081831, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdcb20081831, replyNumber=0, likeNumber=86, createdTime=2020-09-19, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdcb20081831, moduleTitle=J Clin Oncol：恩扎鲁胺治疗转移性前列腺癌时18氟化钠PET/CT和循环肿瘤细胞的时空变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdcb20081831)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395551, encodeId=6a93139555178, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！, objectType=article, longId=200507, objectId=259720050e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=259720050e88, replyNumber=0, likeNumber=101, createdTime=2020-09-12, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=259720050e88, moduleTitle=NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=259720050e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395550, encodeId=60fd13955504d, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=Sci Transl Med：转移性前列腺癌新突破：免疫检查点抑制剂彰显成效！, objectType=article, longId=191332, objectId=39b819133230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39b819133230, replyNumber=0, likeNumber=73, createdTime=2020-04-04, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39b819133230, moduleTitle=Sci Transl Med：转移性前列腺癌新突破：免疫检查点抑制剂彰显成效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39b819133230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395549, encodeId=50af13955491d, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, objectType=article, longId=191239, objectId=94ff191239b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94ff191239b4, replyNumber=0, likeNumber=72, createdTime=2020-04-03, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94ff191239b4, moduleTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94ff191239b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395548, encodeId=71c1139554860, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=Clinical Cancer Res：Cabozantinib联合ADT治疗激素幼稚性转移性前列腺癌, objectType=article, longId=189552, objectId=e06a189552a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e06a189552a1, replyNumber=0, likeNumber=52, createdTime=2020-03-10, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e06a189552a1, moduleTitle=Clinical Cancer Res：Cabozantinib联合ADT治疗激素幼稚性转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e06a189552a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395547, encodeId=fcce139554e2c, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=转移性前列腺癌该如何化疗, objectType=article, longId=184319, objectId=581e1843194a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=581e1843194a, replyNumber=0, likeNumber=56, createdTime=2019-12-08, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=581e1843194a, moduleTitle=转移性前列腺癌该如何化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=581e1843194a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395546, encodeId=d9d713955461d, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=转移性前列腺癌化疗中国专家共识（2019版）, objectType=article, longId=184157, objectId=54c918415ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54c918415ed0, replyNumber=0, likeNumber=59, createdTime=2019-12-05, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54c918415ed0, moduleTitle=转移性前列腺癌化疗中国专家共识（2019版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54c918415ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395545, encodeId=2bc913955458f, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间, objectType=article, longId=183719, objectId=f1bc183e1902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bc183e1902, replyNumber=0, likeNumber=87, createdTime=2019-11-30, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bc183e1902, moduleTitle=2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bc183e1902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395544, encodeId=cee91395544d8, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=Prostate Cancer P D：接受重症监护治疗的转移性前列腺癌患者接受姑息治疗的当前趋势和社会障碍研究, objectType=article, longId=183223, objectId=46cf183223b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46cf183223b5, replyNumber=0, likeNumber=120, createdTime=2019-11-21, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46cf183223b5, moduleTitle=Prostate Cancer P D：接受重症监护治疗的转移性前列腺癌患者接受姑息治疗的当前趋势和社会障碍研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46cf183223b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395543, encodeId=12411395543db, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌, objectType=article, longId=179257, objectId=a1d11e925723, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1d11e925723, replyNumber=0, likeNumber=60, createdTime=2019-09-12, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1d11e925723, moduleTitle=Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1d11e925723)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395542, encodeId=a7aa139554237, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=恩杂鲁胺XTANDI治疗转移性前列腺癌获得FDA的优先审查, objectType=article, longId=178215, objectId=9f1f1e821593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1f1e821593, replyNumber=0, likeNumber=98, createdTime=2019-08-28, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1f1e821593, moduleTitle=恩杂鲁胺XTANDI治疗转移性前列腺癌获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f1f1e821593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395541, encodeId=509e139554125, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=NEJM：恩杂鲁胺与标准一线治疗转移性前列腺癌疗效比较, objectType=article, longId=175199, objectId=28651e51992b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28651e51992b, replyNumber=0, likeNumber=64, createdTime=2019-07-12, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28651e51992b, moduleTitle=NEJM：恩杂鲁胺与标准一线治疗转移性前列腺癌疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28651e51992b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395540, encodeId=7ee91395540c3, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期, objectType=article, longId=164282, objectId=b041164282af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b041164282af, replyNumber=0, likeNumber=79, createdTime=2019-04-16, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b041164282af, moduleTitle=Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b041164282af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395539, encodeId=d26b1395539e1, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, objectType=article, longId=160414, objectId=ea1416041497, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1416041497, replyNumber=0, likeNumber=72, createdTime=2019-02-20, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1416041497, moduleTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1416041497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395538, encodeId=fad3139553883, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=Nat commun：NSD2是转移性前列腺癌的保守驱使因子, objectType=article, longId=156643, objectId=7cb915664370, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cb915664370, replyNumber=0, likeNumber=85, createdTime=2018-12-27, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cb915664370, moduleTitle=Nat commun：NSD2是转移性前列腺癌的保守驱使因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cb915664370)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395537, encodeId=2261139553e1a, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=2018版转移性前列腺癌诊治中国专家共识, objectType=article, longId=156421, objectId=aa8c156421b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa8c156421b0, replyNumber=0, likeNumber=66, createdTime=2018-12-24, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa8c156421b0, moduleTitle=2018版转移性前列腺癌诊治中国专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa8c156421b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395536, encodeId=4b5b13955367d, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=Nat Commun：重磅！转移性前列腺癌新靶点被发现！, objectType=article, longId=155485, objectId=945215548586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=945215548586, replyNumber=0, likeNumber=72, createdTime=2018-12-11, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=945215548586, moduleTitle=Nat Commun：重磅！转移性前列腺癌新靶点被发现！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=945215548586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395535, encodeId=117d1395535f9, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌, objectType=article, longId=144569, objectId=4e5f14456932, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5f14456932, replyNumber=0, likeNumber=104, createdTime=2018-07-18, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5f14456932, moduleTitle=FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e5f14456932)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395534, encodeId=01281395534a4, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=EAU18∣魏强教授团队：区域淋巴结及远处转移性前列腺癌的局部治疗研究进展, objectType=article, longId=133352, objectId=31ec1333525c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31ec1333525c, replyNumber=0, likeNumber=74, createdTime=2018-03-26, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31ec1333525c, moduleTitle=EAU18∣魏强教授团队：区域淋巴结及远处转移性前列腺癌的局部治疗研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31ec1333525c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395533, encodeId=34ab139553311, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, objectTitle=Prostate：转移性前列腺癌相关的P62能够抑制自噬流和促进上皮间质转化, objectType=article, longId=130212, objectId=f25613021214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f25613021214, replyNumber=0, likeNumber=78, createdTime=2018-02-20, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f25613021214, moduleTitle=Prostate：转移性前列腺癌相关的P62能够抑制自噬流和促进上皮间质转化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f25613021214)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性前列腺癌

2020-05-29

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

J Clin Oncol：恩扎鲁胺治疗转移性前列腺癌时18氟化钠PET/CT和循环肿瘤细胞的时空变化

2020-09-19

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！

2020-09-12

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

Sci Transl Med：转移性前列腺癌新突破：免疫检查点抑制剂彰显成效！

2020-04-04

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌

2020-04-03

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

Clinical Cancer Res：Cabozantinib联合ADT治疗激素幼稚性转移性前列腺癌

2020-03-10

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

转移性前列腺癌该如何化疗

2019-12-08

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

转移性前列腺癌化疗中国专家共识（2019版）

2019-12-05

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间

2019-11-30

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

Prostate Cancer P D：接受重症监护治疗的转移性前列腺癌患者接受姑息治疗的当前趋势和社会障碍研究

2019-11-21

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌

2019-09-12

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

恩杂鲁胺XTANDI治疗转移性前列腺癌获得FDA的优先审查

2019-08-28

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

NEJM：恩杂鲁胺与标准一线治疗转移性前列腺癌疗效比较

2019-07-12

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期

2019-04-16

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率

2019-02-20

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

Nat commun：NSD2是转移性前列腺癌的保守驱使因子

2018-12-27

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

2018版转移性前列腺癌诊治中国专家共识

2018-12-24

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

Nat Commun：重磅！转移性前列腺癌新靶点被发现！

2018-12-11

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌

2018-07-18

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

EAU18∣魏强教授团队：区域淋巴结及远处转移性前列腺癌的局部治疗研究进展

2018-03-26

ms24272190615788285182 (审核中...)

前往app查看评论内容

#转移性前列腺癌#

Prostate：转移性前列腺癌相关的P62能够抑制自噬流和促进上皮间质转化

2018-02-20

科室
- - 订阅+
  - 更多科室
工具
服务